Quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) analysis of fruquintinib plus best supportive care (BSC) compared with placebo plus BSC in metastatic colorectal cancer (mCRC): Results from the FRESCO-2 trial

被引：1

作者：

Stintzing, Sebastian

Tabernero, Josep

Satoh, Taroh

Dasari, Arvind

Lonardi, Sara

Eng, Cathy

Garcia-Carbonero, Rocio

Elez, Elena

Yoshino, Takayuki

Sobrero, Alberto F.

Yao, James C.

Kasper, Stefan

Arnold, Dirk

Basic, Edin

Granold, Matthias

Petschulies, Marco

Wu, Liwen

Chen, Lucy

Yang, Zhao

Van Cutsem, Eric

机构：

[1] Charite Univ Med Berlin, Dept Hematol Oncol & Canc Immunol, Berlin, Germany

[2] Vall dHebron Hosp Campus, Vall dHebron Inst Oncol, Barcelona, Spain

[3] Osaka Univ, Grad Sch Med, Dept Gastroenterol Surg, Suita, Japan

[4] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX USA

[5] Veneto Inst Oncol IOV IRCCS, Med Oncol Unit 1, Padua, Italy

[6] Vanderbilt Ingram Canc Ctr, Dept Med, Div Hematol Oncol, Nashville, TN USA

[7] Hosp Univ 12 Octubre Imas12, UCM, Madrid, Spain

[8] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Japan

[9] Azienda Osped San Martino, Dept Med Oncol, Genoa, Italy

[10] Univ Hosp Essen, West German Canc Ctr, Dept Med Oncol, Essen, Germany

[11] AK Altona, Dept Oncol & Hematol, Asklepios Tumorzentrum Hamburg, Hamburg, Germany

[12] Takeda Pharm Vertrieb GmbH & Co KG, Berlin, Germany

[13] Takeda Dev Ctr Amer Inc TDCA, Lexington, MA USA

[14] HUTCHMED Int Inc, Florham Pk, NJ USA

[15] Univ Hosp Gasthuisberg Leuven, Gastroenterol Digest Oncol, Leuven, Belgium

[16] KULeuven, Leuven, Belgium

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期

关键词：

130-231; 261-492-3532-2370-7650-2700; 283-237-255; 261-492-3532-2370-12160; 281-5277-2560; 9; 3; 2; 2461; 1;

D O I：

10.1200/JCO.2024.42.3_suppl.116

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：116 / 116

页数：1

共 50 条

[31] HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND COLORECTAL CANCER (CRC) SYMPTOMS IN METASTATIC CRC: PANITUMUMAB PLUS BEST SUPPORTIVE CARE (BSC) VS. BSC ALONE BY KRAS TUMOR STATUS
Odom, D.
Devercelli, G.
Bennett, L.
Peeters, M.
Wolf, M.
Amado, R.
VALUE IN HEALTH, 2008, 11 (06) : A487 - A487
[32] Quality-adjusted survival of combined nivolumab plus ipilimumab (NIVO plus IPI) or NIVO alone vs IPI among treatment-naive patients (pts) with advanced melanoma (MEL): a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis
Botteman, M.
Shah, R.
Gupte-Singh, K.
Luo, L.
Sabater, J.
Rao, S.
McDermott, D. F.
Atkins, M. B.
Regan, M.
ANNALS OF ONCOLOGY, 2017, 28
[33] Tissue and plasma tumor mutation burden (TMB) as predictive biomarkers in the CO.26 trial of durvalumab plus tremelimumab (D plus T) versus best supportive care (BSC) in metastatic colorectal cancer (mCRC).
Loree, Jonathan M.
Topham, James T.
Kennecke, Hagen F.
Feilotter, Harriet
Keshavarz-Rahaghi, Faeze
Lee, Young S.
Li Weimin
Quinn, Katie
Banks, Kimberly
Renouf, Daniel John
Jonker, Derek J.
Tu Dongsheng
O'Callaghan, Christopher J.
Chen, Eric Xueyu
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
[34] EFFECT OF FRUQUINTINIB PLUS BEST SUPPORTIVE CARE ON EASTERN COOPERATIVE ONCOLOGY GROUP PERFORMANCE STATUS DETERIORATION IN PATIENTS WITH REFRACTORY METASTATIC COLORECTAL CANCER: POST-HOC ANALYSIS OF THE PHASE 3 PLACEBO-CONTROLLED FRESCO-2 STUDY
Aquino, Jeneth
Dasari, Arvind
Eng, Cathy
Yu, Ziji
Chen, Lucy
Sobrero, Alberto
ONCOLOGY NURSING FORUM, 2024, 51 (02)
[35] Early tumor shrinkage (ETS) and depth of response (DpR) in wild-type (WT) RAS tumors from the phase III trial of panitumumab (pmab) plus best supportive care (BSC) versus BSC in chemorefractory metastatic colorectal cancer (mCRC).
Kim, Tae Won
Elme, Anneli
Park, Joon Ho
Udrea, Anghel Adrian
Manojlovic, Nebojsa S.
Guan, Xuesong
Jung, A. Scott
Vrdoljak, Eduard
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[36] An open label, randomized phase III trial evaluating the treatment (tx) effects of panitumumab (pmab) plus best supportive care (BSC) versus BSC in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) and in WT RAS mCRC.
Kim, Tae Won
Elme, Anneli
Kusic, Zvonko
Park, Joon Oh
Udrea, Anghel Adrian
Kim, Sun Young
Ahn, Joong Bae
Valencia, Ricardo Villalobos
Srinivasan, Krishnan
Bilic, Ante
Manojlovic, Nebojsa
Dong, Jun
Guan, Xuesong
Lofton-Day, Catherine
Jung, A. Scott
Vrdoljak, Eduard
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
[37] Avelumab plus axitinib (Ave plus Axi) vs sunitinib (Sun) in advanced renal cell carcinoma (aRCC): Final analysis of patient (pt)-reported outcomes (PROs) and quality-adjusted time without symptoms or toxicity (Q-TWiST)
Venugopal, B.
Choueiri, T. K.
Penkov, K. D.
Albiges, L.
Uemura, H.
Larkin, J.
Tomita, Y.
Wang, J.
Hoffman, J.
Gerhold-Ay, A.
Kieslich, P.
Motzer, R. J.
ANNALS OF ONCOLOGY, 2024, 35 : S1017 - S1018
[38] A QUALITY-ADJUSTED TIME WITHOUT SYMPTOMS OR TOXICITY (Q-TWIST) ANALYSIS OF SYSTEMIC THERAPY VERSUS STANDARD OF CARE INTRAVESICAL TREATMENT (BCG) IN NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS
Rivera-Marquez, Genesis
Walter, Beatriz
Dolan, Rebecca
Belfield, Sonia
Valera, Vladimir A.
JOURNAL OF UROLOGY, 2024, 211 (05): : E991 - E992
[39] A randomized, double-blind, placebo-controlled, multi-centered phase 3 trial comparing fruquintinib versus placebo plus best supportive care in Chinese patients with metastatic colorectal cancer (FRESCO).
Li, Jin
Qin, Shukui
Bai, Yuxian
Deng, Yanhong
Yang, Lei
Xu, Rui-Hua
Chen, Zhendong
Zhong, Haijun
Pan, Hongming
Shu, Yonggian
Yuan, Ying
Xu, Nong
Zhou, Jianfeng
Liu, Tianshu
Ma, Dong
Wu, Changping
Cheng, Ying
Fan, Songhua
Hua, Ye
Su, Weiguo
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[40] A quality-adjusted time without symptoms and toxicity (Q-TWiST) analysis comparing nivolumab plus ipilimumab (N plus I) or nivolumab plus chemotherapy (N plus CT) versus CT in patients (pts) with advanced esophageal squamous cell carcinoma (ESCC): CheckMate 648.
Chau, Ian
Bridgewater, John A.
Wyrwicz, Lucjan
Greenwood, Mike
Blum, Steven I.
Moreno-Koehler, Alejandro
Worthy, Gill
Taylor, Fiona
Davis, Catherine
Chen, Clara
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 251 - 251

← 1 2 3 4 5 →